ATE478069T1 - 3,4-dihydro-2h-benzoä1,4üoxazin- und 3,4-dihydro- 2h-benzoä1,4üthiazin-verbindungen als alpha2c- adrenorezeptor-antagonisten - Google Patents

3,4-dihydro-2h-benzoä1,4üoxazin- und 3,4-dihydro- 2h-benzoä1,4üthiazin-verbindungen als alpha2c- adrenorezeptor-antagonisten

Info

Publication number
ATE478069T1
ATE478069T1 AT06802156T AT06802156T ATE478069T1 AT E478069 T1 ATE478069 T1 AT E478069T1 AT 06802156 T AT06802156 T AT 06802156T AT 06802156 T AT06802156 T AT 06802156T AT E478069 T1 ATE478069 T1 AT E478069T1
Authority
AT
Austria
Prior art keywords
benzoä1
dihydro
4üoxazine
compounds
adrenoreceptor antagonists
Prior art date
Application number
AT06802156T
Other languages
English (en)
Inventor
Kevin Mccormick
Christopher Boyce
Neng-Yang Shih
Robert Aslanian
Pietro Mangiaracina
Lera Ruiz Manuel De
Younong Yu
Purakkattle Biju
Chia-Yu Huang
Bo Liang
Ruiyan Liu
Rong-Qiang Liu
Lisa Guise-Zawacki
Original Assignee
Schering Corp
Pharmacopeia Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Pharmacopeia Llc filed Critical Schering Corp
Application granted granted Critical
Publication of ATE478069T1 publication Critical patent/ATE478069T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT06802156T 2005-08-25 2006-08-23 3,4-dihydro-2h-benzoä1,4üoxazin- und 3,4-dihydro- 2h-benzoä1,4üthiazin-verbindungen als alpha2c- adrenorezeptor-antagonisten ATE478069T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71145305P 2005-08-25 2005-08-25
PCT/US2006/032917 WO2007024949A2 (en) 2005-08-25 2006-08-23 Alpha2c adrenoreceptor agonists

Publications (1)

Publication Number Publication Date
ATE478069T1 true ATE478069T1 (de) 2010-09-15

Family

ID=37668030

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06802156T ATE478069T1 (de) 2005-08-25 2006-08-23 3,4-dihydro-2h-benzoä1,4üoxazin- und 3,4-dihydro- 2h-benzoä1,4üthiazin-verbindungen als alpha2c- adrenorezeptor-antagonisten

Country Status (21)

Country Link
US (2) US20070093477A1 (de)
EP (1) EP1934203B1 (de)
JP (2) JP2009506051A (de)
KR (1) KR20080037070A (de)
CN (1) CN101374830A (de)
AR (1) AR057771A1 (de)
AT (1) ATE478069T1 (de)
AU (1) AU2006283109A1 (de)
BR (1) BRPI0615021A2 (de)
CA (1) CA2620173A1 (de)
DE (1) DE602006016303D1 (de)
EC (1) ECSP088221A (de)
ES (1) ES2348997T3 (de)
IL (1) IL189678A0 (de)
NO (1) NO20081427L (de)
PE (1) PE20070519A1 (de)
RU (1) RU2008110902A (de)
SG (1) SG165315A1 (de)
TW (1) TWI329643B (de)
WO (1) WO2007024949A2 (de)
ZA (1) ZA200802495B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700592B2 (en) 2005-08-25 2010-04-20 Schering Corporation α2C adrenoreceptor agonists
EP1934203B1 (de) 2005-08-25 2010-08-18 Schering Corporation 3,4-dihydro-2H-benzo[1,4]oxazin- und 3,4-dihydro-2H-benzo[1,4]thiazin-VERBINDUNGEN ALS ALPHA2C-ADRENOREZEPTOR-ANTAGONISTEN
JP5099814B2 (ja) * 2006-02-02 2012-12-19 田辺三菱製薬株式会社 含窒素複素二環式化合物
US7601716B2 (en) * 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
EP2086959B1 (de) * 2006-11-02 2011-11-16 F. Hoffmann-La Roche AG Substituierte 2-imidazole als modulatoren der mit spurenaminen assoziierten rezeptoren
MX2009005047A (es) * 2006-11-16 2009-05-25 Hoffmann La Roche 4-imidazoles sustituidos.
CN101702905A (zh) * 2007-02-13 2010-05-05 先灵公司 功能选择性α2C肾上腺素能受体激动剂
CA2678072A1 (en) * 2007-02-13 2008-08-21 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
JP2010518161A (ja) * 2007-02-13 2010-05-27 シェーリング コーポレイション 機能選択性α２Ｃアドレナリン受容体アゴニストとしてのクロマン誘導体および類似体
WO2009035997A2 (en) 2007-09-14 2009-03-19 Cara Therapeutics, Inc. Benzo-fused heterocycles
UA105182C2 (ru) * 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
WO2010017120A1 (en) * 2008-08-04 2010-02-11 Schering Corporation Cyclopropylchromene derivatives as modulators of the alpha-2c receptor
US20110172217A1 (en) * 2008-09-05 2011-07-14 Shionogi & Co., Ltd. Ring-fused morpholine derivative having pi3k-inhibiting activity
WO2010033495A2 (en) * 2008-09-16 2010-03-25 Schering Corporation Functionally selective azanitrile alpha2c adrenoreceptor agonists
TW201026688A (en) * 2008-10-07 2010-07-16 Schering Corp Benzodioxan analogues as alpha2C adrenergic receptor modulators
WO2010042473A1 (en) 2008-10-07 2010-04-15 Schering Corporation Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
US8455522B2 (en) 2009-05-15 2013-06-04 Novartis Ag Benzoxazolone derivatives as aldosterone synthase inhibitors
MX2011012202A (es) 2009-05-15 2011-12-08 Novartis Ag Derivados de 5-piridin-3-il-1,3-dihidro-indol-2-ona y su uso como moduladores de a sintanasa de aldosterona y/o de cyp11b1.
BR112012002780A2 (pt) * 2009-08-10 2017-02-21 Bellus Health Inc métodos, compostos, e composições para a aplicação de ácido 1,3-propanodisulfônico
KR20130121891A (ko) * 2010-12-01 2013-11-06 얀센 파마슈티카 엔.브이. Ｃｃｒ２의 4-치환된-사이클로헥실아미노-4-피페리디닐-아세트아미드길항제
EP2736330A4 (de) * 2011-07-29 2015-05-27 Tempero Pharmaceuticals Inc Verbindungen und verfahren
US9677892B2 (en) * 2011-08-16 2017-06-13 Walk Score Management LLC System and method for assessing quality of transit networks at specified locations
WO2013076590A1 (en) * 2011-11-23 2013-05-30 Oxygen Healthcare Research Pvt. Ltd Benzothiazine compounds as h3 receptor ligands
CN103588722A (zh) * 2012-08-17 2014-02-19 苏州中科天马肽工程中心有限公司 6-硝基-2h-1,4-苯并恶嗪-3(4h)-酮的合成方法
US11174252B2 (en) 2018-02-15 2021-11-16 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
US10689360B1 (en) * 2019-01-30 2020-06-23 Insilico Medicine Ip Limited TLR inhibitors
US11807622B2 (en) 2019-01-30 2023-11-07 Insilico Medicine Ip Limited TLR 9 inhibitors
CA3150689A1 (en) * 2019-08-14 2021-02-18 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
KR20220141328A (ko) * 2020-02-12 2022-10-19 큐라데브 파마 프라이버트 리미티드 소분자 sting 길항제
PE20251235A1 (es) * 2022-06-10 2025-04-29 Sapiensbio Inc Compuesto novedoso y composicion farmaceutica que comprende la misma como ingrediente activo
WO2024025896A2 (en) * 2022-07-25 2024-02-01 Evommune, Inc. Protein kinase c (pkc) theta inhibitor compounds
WO2025099111A1 (en) 2023-11-10 2025-05-15 Wella Germany Gmbh New telescoping syntheses of 6-hydroxy-benzomorpholine (3,4-dihydro-2h-1,4-benzoxazin-6-ol)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
US5856106A (en) * 1995-11-01 1999-01-05 Biotransplant, Inc. Determination of antibody production against administered therapeutic glycoproteins, especially monoclonal antibodies
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US5977134A (en) * 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
PT1036065E (pt) * 1997-12-04 2004-09-30 Allergan Inc Derivados de imidazol substituidos com actividade do tipo agonista nos receptores alfa 2b ou 2b/2c adrenergicos
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US20030087962A1 (en) * 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
TWI283669B (en) * 1999-06-10 2007-07-11 Allergan Inc Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
WO2002005853A2 (en) * 2000-07-14 2002-01-24 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
FI20022159A0 (fi) 2002-12-05 2002-12-05 Orion Corp Uusia farmaseuttisia yhdisteitä
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
AU2005290008A1 (en) * 2004-09-24 2006-04-06 Allergan, Inc. 4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
US7700592B2 (en) * 2005-08-25 2010-04-20 Schering Corporation α2C adrenoreceptor agonists
EP1934203B1 (de) 2005-08-25 2010-08-18 Schering Corporation 3,4-dihydro-2H-benzo[1,4]oxazin- und 3,4-dihydro-2H-benzo[1,4]thiazin-VERBINDUNGEN ALS ALPHA2C-ADRENOREZEPTOR-ANTAGONISTEN

Also Published As

Publication number Publication date
BRPI0615021A2 (pt) 2011-04-26
JP2009506051A (ja) 2009-02-12
JP2009185016A (ja) 2009-08-20
ES2348997T3 (es) 2010-12-21
EP1934203A2 (de) 2008-06-25
CA2620173A1 (en) 2007-03-01
TWI329643B (en) 2010-09-01
CN101374830A (zh) 2009-02-25
AR057771A1 (es) 2007-12-19
HK1118812A1 (en) 2009-02-20
SG165315A1 (en) 2010-10-28
DE602006016303D1 (de) 2010-09-30
PE20070519A1 (es) 2007-07-13
RU2008110902A (ru) 2009-09-27
IL189678A0 (en) 2008-08-07
US20070093477A1 (en) 2007-04-26
AU2006283109A1 (en) 2007-03-01
TW200740799A (en) 2007-11-01
WO2007024949A3 (en) 2007-06-07
EP1934203B1 (de) 2010-08-18
NO20081427L (no) 2008-05-23
KR20080037070A (ko) 2008-04-29
ZA200802495B (en) 2008-12-31
US7985748B2 (en) 2011-07-26
US20100173823A1 (en) 2010-07-08
ECSP088221A (es) 2008-03-26
WO2007024949A2 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
ATE478069T1 (de) 3,4-dihydro-2h-benzoä1,4üoxazin- und 3,4-dihydro- 2h-benzoä1,4üthiazin-verbindungen als alpha2c- adrenorezeptor-antagonisten
NO20053161D0 (no) Mikrobedrepende sammensetning.
ATE441639T1 (de) 2,4-diamino-pyrimidine als aurora inhibitoren
PT2878307T (pt) Composição imunogénica.
BRPI0614205A2 (pt) composto, composição farmacêutica, e, uso de composto
ATE517883T1 (de) Imidazolderivate als funktionelle selektive agonisten des alpha2c-adrenorezeptors
ATE469145T1 (de) 4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-
ATE477257T1 (de) Piperidinylamino-thienoä2,3-dü- pyrimidinverbindungen
BRPI0813341A2 (pt) " uso de compostos, composições curáveis, e, uso de composições curáveis ".
DE602005027567D1 (de) 1-aza-bicycloä3.3.1ünonane
DE602007001681D1 (de) 1,3-dioxan-carboxylsäuren
EP1746141A4 (de) Verdickungsmittel
DE602004000946D1 (de) Dimethylpolysiloxan -Zusammensetzung
DE602005017191D1 (de) Geruchsreduzierte waschstück-zusammensetzung
EP1811842A4 (de) 3,3'-diindolylmethan immunaktivierende zusammensetzungen
FR2871686B1 (fr) Composition anti-decoloration
DE602006008937D1 (de) N-amidderivate von 8-azabicycloä3.2.1üoct-3-yl als ccr1-antagonisten
BRPI0614413A2 (pt) composto, e, composição farmacêutica
BRPI0614412A2 (pt) composto, e, composição farmacêutica
DK1863791T5 (da) 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl-piperidiner som CGRP-antagonister
FR2861290B1 (fr) Composition cosmetique thermogonflante.
ATE538121T1 (de) 1,5,6-substituierte-2-oxo-3-cyano-1,6a- diazatetrahydrofluoranthene als antiinfektionsmittel
DK1960510T3 (da) Ammoniakspecifik 5'-xmp-aminasemutant
EP1940415A4 (de) 19,23,24,25,26,27-hexanor-1alpha-hydroxyvitamin d3
FR2891547B1 (fr) Compositions bitume-polymere.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties